Back to results
US 11,826,344 B2Granted
Composition, method of manufacture, and use of site-specific delivery of bruceolides for treatment of cancer and other diseases
AssigneeHoward University
InventorSimeon Kolawole Adesina
Life of this patent
Estimating the term…
Abstract
Disclosed are bruceolides for the treatment of cancer, and other diseases, selectively targeting unwanted cells. The disclosed bruceolides may include a site specific cleavable moiety inhibiting the chemotoxic activity until cleaved, i.e., removed, within and/or near a cancer to be treated. As to facilitate selective delivery to cancer tumors, the disclosed bruceolides may be loaded into, attached to or otherwise carried by nanoparticles.
Claims15
A chemotherapeutic formulation comprising:
- a nanoparticle loaded with a chemotherapeutic agent, the chemotherapeutic agent having the general Formula (1)
- wherein R1, R2, R3 and R4 are each independently selected from a site specific cleavable moiety, an alkyl, and hydrogen, and
- at least one of R1, R2, R3 and R4 is a site specific cleavable moiety sensitive to a protease.
A chemotherapeutic formulation comprising:
- a nanoparticle loaded with a chemotherapeutic agent, the chemotherapeutic agent having the general Formula (1)
- wherein R1, R2, R3 and R4 are each independently selected from a site specific cleavable moiety, an alkyl, and hydrogen, and
- at least one of R1, R2, R3 and R4 is a site specific cleavable moiety which comprises a peptide moiety.
A chemotherapeutic formulation comprising:
- a nanoparticle loaded with a chemotherapeutic agent, the chemotherapeutic agent having the general Formula (1)
- wherein R1, R2, R3 and R4 are each independently selected from a site specific cleavable moiety, an alkyl, and hydrogen, and
- at least one of R1, R2, R3 and R4 of the chemotherapeutic agent is a site specific cleavable moiety sensitive to glutathione.
Dependencies are inferred from the claim text.